Synthesis and structure-activity relationship of substitutions at the C-1 position of Δ9-tetrahydrocannabinol

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 4, 2010, Pages 1424-1426

  Burdick, David ^a   DeOrazio, Russell ^a   Guzzo, Peter ^a   Habershaw, Alicia ^a   Helle, Mark ^a   Paul, Bernard ^a   Wolf, Mark ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

9 Tetrahydrocannabinol; Cannabinoid receptor type 1; Cannabinoid receptor type 2

Indexed keywords

DRONABINOL;

ARTICLE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CATALYSIS; MOLECULAR STRUCTURE; PALLADIUM; RECEPTORS, CANNABINOID; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROCANNABINOL;

EID: 75449083269     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.092     Document Type: Article

References (22)

1. Pertwee R.G. Curr. Med. Chem. 6 (1999) 635
2. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. J. Pharmacol. Rev. 54 (2002) 161
3. Hertzog D.L. Expert Opin. Ther. Patents 14 (2004) 1435
4. Grotenhermen F. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 507
5. Razdan R.K. Pharmacol. Rev. 38 (1986) 75
6. Crocker P.J., Mahadevan A., Wiley J.L., Martin B.R., and Razdan R.K. Bioorg. Med. Chem. Lett. 17 (2007) 1504
7. Burdick, D. C.; Collier, S. J.; Jos, F. Biolatto, B.; Bernhard, P.; Meckler, H.; Helle, M.; Habershaw, A. J. U.S. Patent 2007/0093665 A1.
8. Wolfe J.P., Åhman J., Sadighi J.P., Singer R.A., and Buchwald S.L. Tetrahedron Lett. 38 (1997) 6367
9. Teplý F., Stará I.G., Starý I., Kollárovič A., Šaman D., Vyskočil S., and Fiedler P. J. Org. Chem. 68 (2003) 5193
10. Selnick H.G., Smith G.R., and Tebben A.J. Synth. Commun. 25 (1995) 3255
11. Lou R., VanAlstine M., Sun X., and Wentland M.P. Tetrahedron Lett. 44 (2003) 2477
12. Jiang G., Stalewski J., Galyean J.D., Schteingart C., Broqua P., Aebi A., Aubert M.L., Semple G., Robson P., Akinsanya K., Haigh R., Riviere P., Trojnar J., Junien J.L., and Rivier J.E. J. Med. Chem. 44 (2001) 453
13. Kreis M., and Braese S. Adv. Synth. Catal. 347 (2005) 313
14. Arnould J.C., Didelot M., Cadilhac C., and Pasquet M.J. Tetrahedron Lett. 37 (1996) 4523
15. 1H NMR, APCI or ESI mass spectrum analysis, and HPLC analysis. Structural analysis was also confirmed by COSY and NOESY on most of the final targets.
16. 2 radioligand binding assays.
17. Compton D.R., Rice K.C., DeCosta B.R., Razdan R.K., Melvin L.S., Johnson M.R., and Martin B.R. J. Pharmacol. Exp. Ther. 265 (1993) 218
18. Rinaldi-Carmona M., Calandra B., Shire D., Bouaboula M., Oustric D., Barth F., Casellas P., Ferrara P., and Le Fur G. J. Pharmacol. Exp. Ther. 278 (1996) 871
19. Munro S., Thomas K.L., and Abu-Shaar M. Nature 365 (1993) 61
20. Huffman J.W. Curr. Pharm. Des. 6 (2000) 1323
21. Rhee M.-H., Vogel Z., Barg J., Bayewitch M., Levy R., Hanus L., Breuer A., and Mechoulam R. J. Med. Chem. 40 (1997) 3228
22. Worm K., Zhou Q.J., Stabley G.J., DeHaven R.N., and Dolle R.E. Bioorg. Med. Chem. Lett. 17 (2007) 3652